Morpholinoethylthioethoxybenzimidazole - instructions for use, doses, side effects, contraindications

Clinical and pharmacological group: & nbsp

Anxiolytics

Included in the formulation

Neurophasole

concentrate d / infusion

LEKKO, ZAO Russia

АТХ:

N.05.B Anxiolytics

Pharmacodynamics:

The drug is a selective non-benzodiazepine anxiolytic, due to interaction with σ₁receptors of the nerve cells of the brain preventing the development of membrane-dependent changes in GABA receptors.

Across σ₁receptors, the phospholipid framework of the receptor structures of the cell surface is restored; normalization of the calcium balance; counteracting glutamate excitotoxicity and increased production of nitric oxide; restoration of the deficit of nerve growth factors. Morpholinoethylthioethoxybenzimidazole increases the survival of neurons and reduces the severity of cytotoxic reactions in the damaging effects of oxidative stress and glutamate, normalizes the level of cannase-3, one of the main enzymes activated by apoptosis. The drug has a stimulating effect on the formation of neurotrophic brain factors - NGF (nerve growth factor, nerve growth factor) and BDNF (brain-derived neurotrophic-factor - cerebral neurotrophic factor).

The drug also increases the bioenergetic potential of nerve cells and protects them from damage (has a neuroprotective effect).

The drug has a protective effect on cells of the penumbra zone in conditions of local ischemia, reduces the severity of post-insult disorders and accelerates the restoration of neurologic functions. In cerebral ischemia, the drug suppresses the NO-synthase pathway of formation of nitric oxide in neurons of the brain, prevents the increase in NO-synthase activity. It causes an improvement in energy metabolism, restoring the activity of succinate dehydrogenase in brain ischemia. Promotes increased cerebral blood flow in ischemic conditions, without affecting systemic arterial pressure. The participation of GABA-ergic system in the implementation of cerebrovascular and neuroprotective action of the drug was established.

Pharmacokinetics:

Quickly and completely absorbed from the gastrointestinal tract, metabolized in the liver, the half-life is between 16.8 and 81.6 minutes. Excreted in the form of metabolites and partially unchanged through the gastrointestinal tract and the kidneys. Long-term use of the drug leads to its cumulation.

Indications:

- notyrocirculatory dystonia;

- premenstrual syndrome;

- sleep disorders;

- alcohol withdrawal syndrome;

- somatic diseases of different etiology, including oncological and dermatological diseases;

- neurasthenia;

- adaptation disorders;

- talarm conditions;

- alleviation of the refusal of smoking syndrome;

- cerebral infarction (ischemic stroke).

ICD-10

V.F10-F19.F10.3 Mental and behavioral disorders caused by alcohol use - withdrawal symptoms

V.F10-F19.F17.3 Mental and behavioral disorders caused by the use of tobacco - the abstinence state

V.F40-F48.F41.1 Generalized anxiety disorder

V.F40-F48.F41.9 Anxiety disorder, unspecified

V.F40-F48.F43 Reaction to severe stress and adaptation disorders

V.F40-F48.F45.9 Somatoform disorder, unspecified

V.F40-F48.F48.0 Neurasthenia

V.F50-F59.F51 Sleep disorders of inorganic etiology

VI.G40-G47.G47.8 Other sleep disorders

VI.G90-G99.G90 Disorders of the autonomic nervous system

IX.I10-I15.I10 Essential [primary] hypertension

IX.I20-I25.I20 Angina pectoris [angina pectoris]

X.J40-J47.J45 Asthma

XI.K55-K63.K58 Irritable Bowel Syndrome

XIII.M30-M36.M32 Systemic lupus erythematosus

XIV.N80-N98.N94.3 Premenstrual tension syndrome

XXI.Z55-Z65.Z60 The problems associated with adaptation to lifestyle changes

Contraindications:

- the period of breastfeeding;

- pregnancy;

- age to 18 years;

- hypersensitivity;

- intolerance to galactose, deficiency of lactase or glucose-galactose malabsorption.

Carefully:

No data.

Pregnancy and lactation:

The category of FDA recommendations is not defined. The drug is contraindicated in breastfeeding and during pregnancy.

Dosing and Administration:

Oral after eating 10 mg 3 times a day, the course - 2-4 weeks. At the insistence of the doctor, the daily dose can be increased to 60 mg per day, and the duration of the course is increased to 3 months.

The drug is also used as part of complex therapy in the form of intravenous drip infusions in a dose of 10 mg 2 times a day. The recommended duration of treatment is 10 days.

Before use, 10 mg of the drug is diluted in 150-200 ml of 0.9% sodium chloride solution, the recommended rate of administration is 40-60 drops per minute.

Side effects:

Hypersensitivity, gpain in the head.

Overdose:

Increased drowsiness, withfood effect.

Treatment: 20% solution caffeine sodium benzoate 1 ml 2-3 times a day subcutaneously.

Interaction:

The drug enhances the anxiolytic effect of diazepam and the anticonvulsant effect of carbamazepine.

Special instructions:

The purpose of the drug is especially recommended for patients with predominantly asthenic personality traits in the form of anxious suspicion, uncertainty, increased vulnerability and emotional lability, a tendency to emotional-stressful reactions.

Influence on the ability to drive vehicles and work with machinery.

The drug does not affect the ability to drive vehicles and control mechanisms.

Instructions

Morpholinoethylthioethoxybenzimidazole (Morpholinoethylthioethoxybenzimidazole)